AbbVie G.K. is a Japanese subsidiary of the global pharmaceutical company AbbVie. It was established in 2007 as a result of the merger between Abbott Laboratories and Kosan Biosciences.
AbbVie G.K. has been actively involved in clinical research and development, with a focus on innovative treatments for various diseases. The company has a strong commitment to advancing medical science and improving patient outcomes.
One of the key areas of focus for AbbVie G.K. is the development of new treatments for oncology and immunology. The company has been investing heavily in research and development, with a goal of bringing new and innovative therapies to patients in need.
AbbVie G.K. has a robust pipeline of clinical trials, with multiple studies underway to evaluate the safety and efficacy of new treatments.
Readers also liked: B P C L Share
Clinical Trials
AbbVie's involvement in various clinical trials is a significant aspect of their research and development efforts.
Anastrozole, also known as Arimidex, was tested in one trial.
Potassium nitrate was studied in two separate trials.
Sodium fluoride was also tested in two trials.
Mycophenolate, sold under the brand name CellCept, was the focus of one trial.
Folic acid was tested in a single trial.
Wild blueberry extract was studied in one trial.
Thrombopoietin was the subject of a single trial.
For your interest: Credit One Bank Mobile News
Frequently Asked Questions
What is AbbVie's biggest drug?
AbbVie's biggest drug is Humira, a medication used to treat arthritis, psoriasis, and Crohn's disease. It generates more than half of AbbVie's total annual sales.
What is AbbVie's new weight loss drug?
AbbVie's new weight loss drug, Gubamy, is a once-weekly injection that mimics the hormone amylin to regulate blood sugar and appetite. It's currently in Phase 1 clinical trials, showing promise in suppressing eating and slowing digestion.
Featured Images: pexels.com
